Maximum recommended dose of olmesartan

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Maximum Recommended Dose of Olmesartan for Hypertension

Olmesartan Maximum Dose in Adults

The maximum recommended daily dose of olmesartan for adults is 40 mg per day. This dose is considered effective for the treatment of hypertension and is supported by clinical studies showing its efficacy and safety profile at this level 12346. For patients with severe renal insufficiency (creatinine clearance <20 mL/min) or moderate hepatic insufficiency (Child-Pugh score 7–9), the daily dose should not exceed 20 mg .

Olmesartan in Combination Therapy

When olmesartan is used in combination with hydrochlorothiazide, the maximum recommended dose is 40 mg of olmesartan with 25 mg of hydrochlorothiazide per day. Dose adjustments can be made after 2 to 4 weeks as needed, but should not exceed this combination maximum 236.

Dose-Response and Efficacy

Clinical studies have shown that olmesartan produces a dose-dependent reduction in blood pressure, with the 20 mg dose often considered optimal for many patients. However, higher doses up to 40 mg provide additional blood pressure lowering and are well tolerated, especially in patients who do not achieve target blood pressure with lower doses or monotherapy 4679. Doses above 40 mg have been studied but are not generally recommended for routine clinical use .

Pediatric Dosing

For pediatric patients aged 6 to 16 years, dosing is based on body weight: 10 mg daily for those weighing less than 35 kg, and 20 mg daily for those weighing 35 kg or more . The maximum dose in pediatric patients should not exceed these recommendations.

Conclusion

The maximum recommended dose of olmesartan for adults is 40 mg per day, with lower limits advised for patients with significant renal or hepatic impairment. In combination therapy with hydrochlorothiazide, the maximum is 40 mg/25 mg per day. These dosing recommendations are supported by multiple clinical studies demonstrating both efficacy and safety at these levels.

Sources and full results

Most relevant research papers on this topic

Olmesartan medoxomil: an angiotensin II-receptor blocker.

Olmesartan medoxomil is an effective angiotensin II-receptor blocker for treating hypertension, with a favorable adverse-effect and drug-interaction profile.

Systematic Review

2003·

52citations

·Julie A Brousil et al.

HIGHLIGHTS OF PRESCRIBING INFORMATION

The recommended starting dose for olmesartan/hydrochlorothiazide combination is 40/12.5 mg for olmesartan and 20/12.5 mg for hydrochlorothiazide.

2018·

0citations

Body as a Whole : chest pain , back pain , peripheral edema Central and Peripheral Nervous System : vertigo Gastrointestinal : abdominal pain

The recommended starting doses for patients not adequately controlled with olmesartan or hydrochlorothiazide monotherapy are 40/12.5 mg and 20/12.5 mg, respectively, with a maximum dose of 40 mg/25 mg.

2016·

0citations

Clinical efficacy and tolerability of olmesartan.

Olmesartan effectively reduces diastolic blood pressure in patients with mild to moderate hypertension, with a 20-mg dose being optimal and a good safety profile.

Meta-Analysis

2004·

28citations

·H. Brunner

The Use of Modeling and Simulation to Guide Clinical Development of Olmesartan Medoxomil in Pediatric Subjects

Olmesartan medoxomil effectively reduces blood pressure in pediatric patients aged 6-16 years, with 10 mg for those weighing 35 kg and 20 mg for those weighing 35 kg.

Rigorous Journal

2012·

9citations

·D. Salazar et al.

Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide

Combination therapy with high-dose olmesartan (40 mg) and hydrochlorothiazide (HCTZ) is an effective and safe treatment option for controlling blood pressure in patients with mild-to-severe hypertension.

Literature Review

2010·

12citations

·L. Rump et al.

Dose-Dependent Arterial Destiffening and Inward Remodeling After Olmesartan in Hypertensives With Metabolic Syndrome

40 and 80 mg olmesartan significantly remodel and destiffen arterial walls during long-term treatment, partly independently of blood pressure, compared to 20 mg.

RCTRigorous JournalHighly Cited

2014·

86citations

·S. Laurent et al.

Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension

Olmesartan, at its starting dose, is more effective than other ARBs in reducing cuff diastolic blood pressure in patients with essential hypertension.

RCTLarge Human TrialHighly Cited

2001·

278citations

·S. Oparil et al.

АНТИГИПЕРТЕНЗИВНАЯ ЭФФЕКТИВНОСТЬ ОЛМЕСАРТАНА В СРАВНЕНИИ С ДРУГИМИ АНТАГОНИСТАМИ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II: ОБЗОР РАНДОМИЗИРОВАННЫХ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ

Olmesartan has a greater blood pressure-lowering effect than other angiotensin II type I receptor blockers, with clinically relevant differences in maximal efficacy and per-label recommended doses.

Systematic Review

2010·

0citations

·Ф. Заннад et al.

COMPARATIVE BIOAVAILABILITY OF A FIXED-DOSE COMBINATION TABLET OF OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE IN HEALTHY KOREAN VOLUNTEERS.

The generic formulation of olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg tablet is bioequivalent to the reference formulation of Olmetec Plus 20/12.5 mg tablet in terms of pharmacokinetic parameters.

RCT

2016·

0citations

·R. Zheng et al.

Try another search

history of the theory of relativity

glucagon-like peptide-1 receptor agonist alternatives

collagen daily recommended intake

evidence for the expansion of the universe

chromium recommended daily intake

planetary characteristics and differences